IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.306
NA - Nord America 632
EU - Europa 310
SA - Sud America 229
AF - Africa 12
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.494
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.685
US - Stati Uniti d'America 604
CN - Cina 334
BR - Brasile 182
HK - Hong Kong 141
VN - Vietnam 85
IT - Italia 82
DE - Germania 52
FI - Finlandia 27
NL - Olanda 27
GB - Regno Unito 26
EE - Estonia 25
AT - Austria 22
IN - India 20
AR - Argentina 18
MX - Messico 14
EC - Ecuador 11
CA - Canada 10
ID - Indonesia 10
UA - Ucraina 10
ZA - Sudafrica 9
FR - Francia 8
JP - Giappone 7
ES - Italia 6
PY - Paraguay 6
SE - Svezia 6
CO - Colombia 5
BD - Bangladesh 4
TR - Turchia 4
AU - Australia 3
PE - Perù 3
RU - Federazione Russa 3
AZ - Azerbaigian 2
CH - Svizzera 2
IE - Irlanda 2
KZ - Kazakistan 2
PH - Filippine 2
PL - Polonia 2
SI - Slovenia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CL - Cile 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GH - Ghana 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
LU - Lussemburgo 1
MA - Marocco 1
MY - Malesia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TW - Taiwan 1
UY - Uruguay 1
VE - Venezuela 1
Totale 5.494
Salva come PNG Salva come JPEG
Città #
Dallas 287
Singapore 211
Hefei 193
Hong Kong 140
Beijing 87
Boardman 54
Ashburn 46
Ho Chi Minh City 33
Shanghai 28
Munich 25
Amsterdam 20
London 18
Rome 18
Turku 18
Hanoi 17
São Paulo 16
Sona 15
Santa Clara 14
Los Angeles 13
Mexico City 10
Vienna 10
Brooklyn 9
Johannesburg 8
Helsinki 7
Rio de Janeiro 7
Council Bluffs 6
Guayaquil 6
Milan 6
Boston 5
Cordova 5
Goiânia 5
Kolkata 5
New York 5
San Francisco 5
Seattle 5
Stockholm 5
Chennai 4
Chicago 4
Florence 4
Nuremberg 4
Salvador 4
Thái Bình 4
Tokyo 4
Asunción 3
Blumenau 3
Brasília 3
Durham 3
Haiphong 3
Hải Dương 3
Joinville 3
Maceió 3
Modena 3
Montreal 3
Nola 3
Pune 3
Santo André 3
Teresina 3
Wesley Chapel 3
Ankara 2
Anyang 2
Baku 2
Barra Bonita 2
Bauru 2
Biên Hòa 2
Bến Cầu 2
Can Tho 2
Catanduva 2
Charlotte 2
Chernivtsi 2
Cornaredo 2
Curitiba 2
Dublin 2
Edmond 2
Hortolândia 2
Indianapolis 2
La Plata 2
Madrid 2
Manila 2
Medellín 2
Mineiros 2
Naples 2
Oniferi 2
Phoenix 2
Phủ Lý 2
Prineville 2
Redondo Beach 2
Resistencia 2
Salto 2
Santa Maria 2
Santiago 2
Shenzhen 2
Sombrio 2
Sorocaba 2
Sydney 2
Tianguá 2
Toyosu 2
Washington 2
Yuncheng 2
Accra 1
Almere Stad 1
Totale 1.517
Salva come PNG Salva come JPEG
Nome #
1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC) 274
112P Measuring time-toxicity and prognostic impact of hospital attendance in early phase cancer trials participants 242
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC 241
1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy 237
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 204
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 203
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung) 203
69P Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors 200
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 198
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade 198
96P Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens 197
Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment 191
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan 191
P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study 190
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 187
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials 180
534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 102
485 Impact of opioid signaling on the tumor microenvironment and clinical outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) 97
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 90
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 88
THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 88
OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 86
Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade 80
T.07.3: CHARACTERISTICS AND OUTCOMES OF IMMUNOTHERAPYRELATED LIVER INJURY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA COMPARED TO PATIENTS WITH ADVANCED SOLID TUMOURS 71
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 67
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 61
Association of Obesity With Survival Outcomes in Patients With Cancer 51
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 44
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 41
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models 34
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 32
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 30
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 29
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 28
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 27
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 27
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis 26
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 26
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 26
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 26
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 25
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A "hypothesis-generator' study from clinical practice 24
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 24
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 24
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 23
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival 23
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials 22
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 22
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 21
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer 21
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 21
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 20
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 20
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 20
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 20
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis 19
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 18
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 18
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors 18
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 18
Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review 18
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC 18
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials 17
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 17
Immunotherapy in Hepatocellular Carcinoma 17
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens 17
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 17
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 16
Diabetes and Immune Checkpoint Inhibitors—Response 16
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 16
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry 16
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer 16
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view 16
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice 16
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 16
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 15
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 15
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes 15
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers 15
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management 15
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 15
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) 14
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 14
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 14
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab 14
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial 14
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry 14
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 14
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer 14
Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival 13
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 13
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 13
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes 13
Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry 12
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 12
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer 12
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 11
Totale 5.584
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202227 0 0 0 0 3 0 0 0 4 0 0 20
2022/20232 0 0 0 0 1 0 0 0 0 0 1 0
2023/2024102 0 10 19 14 7 29 2 3 6 5 5 2
2024/20254.356 26 19 72 19 12 30 148 64 244 276 1.793 1.653
2025/20261.097 298 215 512 72 0 0 0 0 0 0 0 0
Totale 5.584